Cover Image

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractor...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wataru Kikushima (Author), Yoichi Sakurada (Author), Yoshiko Fukuda (Author), Mio Matsubara (Author), Yumi Kotoda (Author), Atsushi Sugiyama (Author), Kenji Kashiwagi (Author)
Format:	Book
Published:	MDPI AG, 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
by: Taiyo Shijo, et al.
Published: (2020)

Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy
by: Misa Kimura, et al.
Published: (2024)

Intravitreal Bevacizumab Injection Effect in Exudative Age Related Macular Degeneration
by: Gholamhossein Yaghoobi, et al.
Published: (2016)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022)

Comparison of the 1-Year Visual and Anatomical Outcomes between Subthreshold Red (670 nm) and Yellow (577 nm) Micro-Pulse Laser Treatment for Diabetic Macular Edema
by: Wataru Kikushima, et al.
Published: (2021)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022)

The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration
by: A. F. Yusupov, et al.
Published: (2024)

Superior cervical gangliectomy induces non-exudative age-related macular degeneration in mice
by: Hernán H. Dieguez, et al.
Published: (2018)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019)

Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study
by: Kyungseon Choi, et al.
Published: (2023)

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies
by: Karasavvidou EM, et al.
Published: (2022)

The role of aflibercept in the management of diabetic macular edema
by: Chang AA, et al.
Published: (2015)

Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series
by: Silvio Zuccarini, et al.
Published: (2022)

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration
by: Panos GD, et al.
Published: (2013)

Incremental economic burden associated with exudative age-related macular degeneration: a population-based study
by: Siin Kim, et al.
Published: (2019)

Intravitreal aflibercept protects photoreceptors of mice against excessive light exposure
by: Yoshiki Kuse, et al.
Published: (2018)

The efficacy and safety of aflibercept and conbercept in diabetic macular edema
by: Cai S, et al.
Published: (2018)

Polymorphic nanobody crystals as long‐acting intravitreal therapy for wet age‐related macular degeneration
by: Shuqian Zhu, et al.
Published: (2023)

Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
by: Gebran Khneizer, et al.
Published: (2017)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
by: Daniele Veritti, et al.
Published: (2023)

Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018)

First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
by: Wissam Aljundi, et al.
Published: (2024)

Features of aflibercept plus hyperbaric oxygen therapy for diabetic macular edema
by: V. O. Drozdov, et al.
Published: (2022)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2019)

Ocular Safety of Intravitreal Injections of Age-Related Macular Degeneration Treatments in a Prospective Observational Cohort Study in Europe
by: Kui Huang, et al.
Published: (2015)

Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration
by: Joanna Dolar-Szczasny, et al.
Published: (2021)

Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis
by: Ba J, et al.
Published: (2015)

Analysis of intravitreal using of anti vegf-medications for diseases of fundus accompanied by exudation and neovascularization
by: N. G. Zavgorodnya, et al.
Published: (2013)

The short-term effects of intravitreal aflibercept injections and dexamethasone implant on ocular hemodynamics in retinal vein occlusions
by: Ciloglu E, et al.
Published: (2019)

A bioengineered anti‐VEGF protein with high affinity and high concentration for intravitreal treatment of wet age‐related macular degeneration
by: Chengnan Huang, et al.
Published: (2024)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021)

Comparing the effectiveness of brolucizumab therapy alone versus that combined with subthreshold micropulse laser exposure in the treatment of diabetic macular edema
by: AO Giyasova, et al.
Published: (2023)

Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial
by: Jinfeng Qu, et al.
Published: (2023)

Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy
by: Vira S. Ponomarchuk, et al.
Published: (2021)

Morphological and ophthalmoscopic features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy
by: Vira S Ponomarchuk, et al.
Published: (2021)

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab
by: Pablo Almuiña-Varela, et al.
Published: (2024)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
by: Messenger WB, et al.
Published: (2013)

NLRP3 Inflammasome: Activation and Regulation in Age-Related Macular Degeneration
by: Jiangyuan Gao, et al.
Published: (2015)